Reversal of dopamine neurons and locomotor ability degeneration in aged rats with SMILAGENIN (cas 126-18-1)

Add time:09/10/2019    Source:sciencedirect.com

The purpose of this paper is to study the effect of smilagenin (SMI) (PYM50028), a sapogenin compound originally identified from Chinese medicinal herb, on dopamine neurons and locomotor ability in aged rats. Experiments were carried out on young and aged Sprague–Dawley rats, which were daily administered with either SMI (18 mg/kg/day) or vehicle (0.5% sodium carboxymethycellulose [CMCNa]). Open-field and rotarod performance tests revealed that behavioral ability was impaired in aged rats and was improved by oral administration of smilagenin. Immunohistochemical data showed that tyrosine hydroxylase (TH)-positive neuron numbers in the substantia nigra pars compacta (unbiased stereological counting) were altered with aging and were increased by smilagenin treatment. Likewise, the dopamine receptor density and the striatal dopamine transporter (DAT) density (125I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane [125I-FP-CIT] autoradiography) were significantly lowered in aged rats as compared to young rats, and treatment with smilagenin significantly elevated the dopamine receptor and DAT density in aged rats. Furthermore, smilagenin enhances glial cell-derived neurotrophic factor (GDNF) release both in the striatum and midbrain. These results indicate a possible role of smilagenin in the treatment of age-related extrapyramidal disorders.

We also recommend Trading Suppliers and Manufacturers of SMILAGENIN (cas 126-18-1). Pls Click Website Link as below: cas 126-18-1 suppliers

Prev:Synthesis and biological evaluation of 3-carbamate SMILAGENIN (cas 126-18-1) derivatives as potential neuroprotective agents
Next:Regulation of M1-receptor mRNA stability by SMILAGENIN (cas 126-18-1) and its significance in improving memory of aged rats)